The Gold Standard
for Peptide Research.
102 evidence-graded profiles. Every mechanism traced to primary literature. Free to read.
Compound record
Retatrutide
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials demonstrated up to 24.2% body weight reduction — the highest achieved by any pharmacotherapy to date. The addition of glucagon agonism enhances energy expenditure and lipid metabolism beyond dual incretin agonists. Phase 3 trials are underway for obesity and NASH.
Specimen index
All 102+ →Retatrutide
Phase IIILY3437943
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials demonstrated up to 24.2% body weight reduction — the highest achieved by any pharmacotherapy to date. The addition of glucagon agonism enhances energy expenditure and lipid metabolism beyond dual incretin agonists. Phase 3 trials are underway for obesity and NASH.
Semaglutide
ApprovedOzempic · Wegovy
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.
Tesamorelin
ApprovedEgrifta · TH9507
Tesamorelin is a stabilized synthetic GHRH analog FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pulsatile GH secretion while preserving natural feedback regulation. Research demonstrates significant visceral adipose tissue reduction, improved lipid profiles, and cognitive benefits, making it a key study compound for metabolic dysfunction.
Ipamorelin
PreclinicalNNC 26-0161
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. Unlike other GHRPs, it stimulates GH release with high selectivity — producing minimal cortisol, ACTH, or prolactin elevation. It is among the most studied GHRPs for its clean GH pulse profile, making it a preferred research peptide for GH axis studies with reduced side effect concern.
CJC-1295
PreclinicalCJC-1295 with DAC · DAC:GRF
CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.
GHK-Cu
PreclinicalCopper Peptide GHK · Glycyl-L-histidyl-L-lysine copper
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Research demonstrates it stimulates collagen, elastin, and glycosaminoglycan synthesis, promotes wound healing, reduces inflammation, and activates protective antioxidant genes. Plasma levels decline with age, making it a significant anti-aging research target.
TB-500
PreclinicalThymosin Beta-4 Fragment · Tβ4 fragment
TB-500 is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring peptide found in virtually all human cells. Research shows it promotes actin polymerization and cell migration, which accelerates wound healing, muscle repair, and vascular growth. It is particularly studied for its ability to reduce inflammation and promote cardiac tissue repair.
BPC-157
PreclinicalBody Protection Compound 157 · PL 14736
BPC-157 is a 15-amino-acid peptide fragment derived from human gastric juice. It is one of the most extensively researched peptides for tissue repair, demonstrating accelerated healing of tendons, ligaments, muscle, bone, and gut lining in animal models. It appears to upregulate growth hormone receptors and promote angiogenesis at injury sites.
Editorial
How this works.
Every profile starts with a PubMed search — not a supplier's product page. We identify the primary literature, note the study design (in vitro, animal model, or human trial), and rate the evidence accordingly. You will always know whether a claim comes from a rat study or a randomized controlled trial.
Profiles follow a fixed structure: mechanism of action, pharmacokinetics (half-life, bioavailability, routes of administration), clinical evidence with direct study links, and a standardized safety profile. The format does not change based on commercial interest in the compound.
Vetted suppliers appear in our partner directory because they publish third-party certificates of analysis and pass our sourcing review — not because they advertise with us. Research profiles are written before any commercial relationship is established, and editorial findings are never altered by partner status.
If you find an error — a miscited study, an outdated half-life figure, a mechanism described incorrectly — email us. We correct it publicly and note the revision in the profile.
PubMed-sourced
Every citation links to its primary study
Standardized format
Same structure, every profile
No paid placements
Editorial independent of supplier relationships
Researcher plan
Free summaries say what.
Full profiles say why.
The free tier covers research status, an overview, and administration routes. The Researcher plan adds the full mechanism of action, pharmacokinetic data, direct PubMed study links with evidence grades, and the compound comparison tool. $12/month.
Research profile
PreclinicalBPC-157
Free
A 15-amino acid partial sequence of Body Protection Compound, derived from human gastric juice. Studied extensively in rodent models for tissue repair, tendon healing, and gastrointestinal protection.
Mechanism of action
BPC-157 upregulates vascular endothelial growth factor (VEGF) and its receptor VEGFR2, promoting angiogenesis at injury sites. It also sensitizes growth hormone receptors on tendon fibroblasts via the FAK-paxillin pathway, and modulates nitric oxide synthesis through…
Researcher plan
Unlock for $12/mo →“The mechanism breakdowns go further than anything I’ve found outside of primary literature. I’ve started sending patients here before appointments.”
Functional medicine practitioner
“PubMed-linked profiles cut my pre-protocol research time in half.”
PhD researcher, biochemistry
“Finally something I can share with colleagues. No anecdotes dressed up as evidence.”
Compounding pharmacist
New peptide research, once a week.
New profiles and PubMed updates. Not a sales email.
No spam. Unsubscribe any time.
Start with the database.
Every profile has a free summary. No account required.